BioWorld

June 18, 2007

Lpath Moving Sphingomab Into Clinic With $16.8M Financing

Lpath Inc. closed the second tranche of an April private placement, for a total financing of $16.8 million to push its lead compound, the anti-angiogenic compound Sphingomab, into the clinic.(BioWorld Today) Read More

TransOral Reports Positive Data From Phase III Trial In Insomnia

Analyst Opinion Divided On La Jolla's Riquent For Lupus

NewCo News: Tempo Hurries To Target Nanoparticle Combo Drugs

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

Illustration of motor neuron connecting to muscle fiber

Research grants support early clinical trials of ALS treatments

BioWorld Science

The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...